WO2022195558 - COMPOSITION FOR USE IN THE TREATMENT OF COVID-19
National phase entry is expected:
Publication Number
WO/2022/195558
Publication Date
22.09.2022
International Application No.
PCT/IB2022/052501
International Filing Date
18.03.2022
Title **
[English]
COMPOSITION FOR USE IN THE TREATMENT OF COVID-19
[French]
COMPOSITION DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE LA COVID-19
Applicants **
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
Inventors
SHUAIB, Muhammad
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
MOURIER, Tobias
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
PAIN, Arnab
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
Priority Data
63/162,834
18.03.2021
US
63/302,197
24.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1792 | |
| EPO | Filing, Examination | 8856 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 3710 |
Total: 15555 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Compositions and methods for treating a SARS-CoV-2 infection are provided. The disclosed compositions and methods are based on an interaction pathways and inhibition of serine 206 phosphorylation of the Nucleocapsid (N) protein of SARS-CoV-2. The compositions include one of more compounds capable of inhibition of phosphorylation of the Nucleocapsid serine 206. The amount of one or more compounds can be effective to, for example, reduce viral replication, reduce one or more symptoms of a disease, disorder, or illness associated with virus, or a combination thereof. Method for identifying a subject as having an elevated risk of developing one or more symptoms associated with severe COVID-19 are also provided.[French]
L'invention concerne des compositions et des procédés pour traiter une infection par le SARS-CoV-2. Les compositions et les procédés de l'invention sont basés sur des voies d'interaction et l'inhibition de la phosphorylation de la sérine 206 de la protéine nucléocapside (N) du SARS-CoV-2. Les compositions comprennent un ou plusieurs composés capables d'inhiber la phosphorylation de la sérine 206 de nucléocapside. La quantité d'un ou de plusieurs composés peut être efficace pour, par exemple, réduire la réplication virale, réduire un ou plusieurs symptômes d'une affection, d'un trouble ou d'une maladie associée au virus, ou une combinaison de ceux-ci. L'invention concerne également un procédé d'identification d'un sujet présentant un risque élevé de développer un ou plusieurs symptômes associés à une forme grave de COVID-19.